Integrated technology platform for accelerated discovery of antiviral antibody therapeutics
Robin G Bombardi,
Jesse H. Erasmus,
Todd J Suscovich,
Lorellin A. Durnell,
Mallorie E Fouch,
Benjamin J Doranz,
Thomas C Linnekin,
Caitlyn H Linde,
Matthew J Gorman,
Steven G Reed,
Dan H. Barouch,
Michael S. Diamond,
James E. Crowe,
Neal Van Hoeven,
Posted 14 May 2020
bioRxiv DOI: 10.1101/2020.05.12.090944 (published DOI: 10.1038/s41551-020-0594-x)
Posted 14 May 2020
The emergence and reemergence of highly virulent viral pathogens with pandemic potential has created an urgent need for accelerated discovery of antiviral therapeutics. Antiviral human monoclonal (mAbs) are promising drug candidates to prevent or treat severe viral diseases, but the long timelines needed for discovery limits their rapid deployment and use. Here, we report the development of an integrated sequence of technologies incorporating advances in single-cell mRNA sequence analysis, bioinformatics, synthetic biology, and high-throughput functional analysis that allowed us to discover highly potent antiviral human mAbs and validate their activity in vivo at an unprecedented scale, speed, and efficiency. In a 78-day study, modeling deployment of a rapid response platform to an outbreak, we isolated >100 individual Zika virus (ZIKV) specific human mAbs, assessed their function, identified 29 broadly-neutralizing mAbs, and verified therapeutic potency of lead candidates with antibody-encoding mRNA formulation and/or IgG protein delivery in mice and nonhuman primates. Our work provides a roadmap for the rapid antibody discovery programs against viral pathogens of global concern. ### Competing Interest Statement J.L., E.D., M.E.F., and B.J.D. are employees of Integral Molecular. B.J.D. is a shareholder of Integral Molecular. G.A. has a financial interest in SeromYx, a company developing platform technology that describes the antibody immune response. G.A. interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. M.S.D. is a consultant for Inbios and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. J.E.C. has served as a consultant for Sanofi and is on the Scientific Advisory Boards of CompuVax and Meissa Vaccines, is a recipient of previous unrelated research grants from Moderna and Sanofi and is founder of IDBiologics. JHE, APK, and NVH are inventors on a patent application describing the NLC formulation. Vanderbilt University has applied for a patent concerning ZIKV antibodies that is related to this work. All other authors declared no competing interests.
- Downloaded 707 times
- Download rankings, all-time:
- Site-wide: 31,807
- In immunology: 865
- Year to date:
- Site-wide: 59,389
- Since beginning of last month:
- Site-wide: 59,389
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!